Clinical Trial Update: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) [Phase 3]

View source ↗

Summary

Phase III trial evaluating AK105 injection plus Anlotinib hydrochloride capsules versus Sorafenib for advanced hepatocellular carcinoma; the study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)
• Anlotinib hydrochloride capsules (anlotinib hydrochloride)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Advanced Hepatocellular Carcinoma (HCC) | Phase 3 | Status: ACTIVE_NOT_RECRUITING